Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue increased due to the recognition of revenue from a new PHR service ordered by pharmaceutical companies, the launch of new users on the PHR platform, and enhancements to its core functions. Selling, general and administrative expenses increased due to upfront investment, but profitability improved as development costs declined.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥564 million (YoY +48.4%) |
| Operating profit | ¥-371 million |
| Ordinary income | ¥-373 million |
| Profit attributable to owners of the parent | ¥-329 million |
| Net income per share | -¥39.13 |
| Equity ratio | End of the current fiscal period 0.2 / End of previous period 20.9 |
| Total assets | ¥786 million |
| Net assets | ¥42 million |
| Full-year earnings forecast | Net Sales ¥1,466 million (YoY +130.5%) / Operating profit ¥-30 million / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Depreciation and amortization | ¥3,593 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of stock acquisition rights ¥18,947 thousand / Extraordinary loss None |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | The Company's subsidiary 株式会社Welbyヘルスケアソリューションズ resolved to conduct a third-party allotment capital increase with TISI株式会社 as the allottee. The planned amount of the capital increase is ¥680.234 million, the payment date is 30 November 2026, and the Company's planned ownership ratio after the capital increase is 61.67%. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | None |
| Issued Shares at Period-End | 8,535,582 |
| Treasury Shares at Period-End | 30 |
| Factors Behind Changes in Business Performance | Revenue increased due to the recognition of revenue from a new PHR service ordered by pharmaceutical companies, the launch of new users on the PHR platform, and enhancements to its core functions. Selling, general and administrative expenses increased due to upfront investment, but profitability improved as development costs declined. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to the recognition of revenue from a new PHR service ordered by pharmaceutical companies, the launch of new users on the PHR platform, and enhancements to its core functions. In terms of earnings, selling, general and administrative expenses increased as a result of organizational expansion and upfront investment in MyKarte and platform development, while profitability improved due to lower development costs.